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Abstract: Behçet’s disease (BD) is a multisystemic disease that is very rare in Malaysia. About 
5% of patients develop central nervous system involvement, termed neuro-Behçet’s. Neuro-
Behçet’s is one of the most serious causes of long-term morbidity and mortality. We report two 
cases of neuro-Behçet’s associated with uveitis (ocular BD) highlighting the clinical presentation, 
diagnostic measurement, and therapeutic management of these cases.
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Introduction
Behçet’s disease (BD) is a multisystemic, chronic relapsing inflammatory disease 
classified as one of the vasculitides.1,2 The pathogenesis is unclear but histopathologi-
cally suggestive of occlusive vasculitis.3–5 BD was first described by a dermatologist in 
patients with the triad of recurrent severe uveitis and painful oral and genitalia ulcers.3 
BD can be further divided into three subtypes: neuro-Behçet’s, entero-Behçet’s, and 
vasculo-Behçet’s.4 Neuro-Behçet’s can be classified further into acute and chronic 
progressive type. Acute neuro-Behçet’s is characterized by remission and exacerbation 
with good response to corticosteroids therapy.5,6 Chronic progressive neuro-Behçet’s is 
intractable and resistant to corticosteroid, cyclophosphamide and azathioprine (AZT).5–7 
On the basis of the involvement of the brain, it is divided into parenchymal; focal or 
multifocal brain parenchyma involvement and nonparenchymal; major cerebral ves-
sels involvement.5,8–10
BD is reported worldwide but is more prevalent in the Eastern Mediterranean 
countries, Middle-East, and Japan.11–13 To the best of our knowledge, only one case 
of BD with vascular involvement has been reported in Malaysia.4 No case of neuro-
Behçet’s has ever been reported in Malaysia. We reported two cases of debilitating 
neuro-Behçet’s with severe panuveitis in Malaysian patients.
Case report
Case 1
A 47-year-old man presented to the ophthalmology clinic in 2001 with bilateral red 
eyes for 4 days duration. He also complained of eye pain, photophobia, floaters, and 
blurring of vision. He had ~5–6 similar attacks of red eye for the past 4 years. Each 
attack of red eye gradually resolved over 2–4 weeks duration. Systemically, he had 
recurrent episodes of painful oral and genital ulcers, which resolved spontaneously 
after several days.
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On ocular examination, the vision was 1/60 in the right 
eye and hand movement in the left eye. Both eyes showed 
features of nongranulomatous panuveitis, perilimbal injec-
tion, keratic precipitates, and moderate anterior chamber 
reaction with 1 mm hypopyon level in the left eye. There was 
presence of moderate vitritis with multiple areas of retinal 
infiltrates bilaterally and multiple retinal hemorrhages in 
the left eye. Intraocular pressure (IOP) was not elevated. 
An infective and connective tissue screening was normal 
except for an elevated erythrocyte sedimentation rate (ESR; 
68 mm/hour).
A diagnosis of BD was made based on the clinical triad 
of uveitis, and oral and genital ulcers. He was treated with 
oral prednisolone 80 mg daily (1.5 mg/kg/day) and topical 
prednisolone acetate 1% 4-hourly for both eyes. The oral 
prednisolone was tapered down 5 mg per week. At 6 weeks 
on tapering dose of oral prednisolone, his vision improved to 
6/12 in the right eye and 1/60 in the left eye with resolving 
of the ocular inflammation clinically. However, he defaulted 
follow-up.
In 2013, he presented to the outpatient clinic with left 
shoulder pain for 6 months duration. There was also left 
upper limb weakness and limited range of movement of his 
shoulder. Prior to that, the patient had recurrent episodes of 
right upper limb weakness and pain, which recovered fully 
without treatment. The left shoulder pain resolved gradu-
ally with analgesics and physiotherapy. However, during the 
course of physiotherapy, he defaulted again.
He came back again 2 years later to the neurology clinic 
with unsteady gait and difficulty in walking for the past 1 
year. It was also associated with hypophonia and dyspha-
gia. However, there was no upper limbs pain or weakness. 
Neurological examination revealed pyramidal weakness 
of both upper and lower limbs with involvement of IX, X, 
and XII cranial nerves. There was also presence of oral 
ulcers  (Figure 1). However, there was no genital ulcer and 
the pathergy test was negative. He was then referred to 
ophthalmology team for further eye assessment. There was 
no specific ocular symptom except for painless progressive 
blurring of vision of both eyes. His vision deteriorated to 
perception to light bilaterally, with old keratic precipitates 
and an immature cataract noted. Fundus examination showed 
bilateral optic atrophy with attenuated retinal vessels and 
pigmentary changes of the retina.
ESR (73 mm/hour) and C-reactive protein (25 mg/L) were 
elevated. Magnetic resonance imaging (MRI) of the brain 
showed small round multiple hyperintense lesions at both 
frontal lobes on T2-weighted and fluid-attenuated  inversion 
recovery images (Figure 2). The lesions were absent on 
T1-weighted image, suggestive of acute or subacute lesion 
of the brain. However, he refused lumbar puncture procedure 
for cerebrospinal fluid (CSF) analysis.
He was diagnosed to have neuro-Behçet’s clinically. He 
was treated with intravenous methylprednisolone 1 g per day 
for 5 days then continued with oral prednisolone 40 mg daily. 
After 3 months, oral AZT 25 mg daily was added and the 
oral prednisolone was tapered down slowly to a maintenance 
dose of 20 mg daily. There was no relapse of disease and no 
progression of his neurological deficit after almost 1 year of 
treatment. He is ambulating well with walking frame. The 
summary of clinical presentation and treatment is shown in 
Table 1.
Case 2
A 25-year-old active young man presented to emergency 
medicine and trauma care in June 2014 for progressive 
bilateral lower limbs weakness and spasticity for the past 
6 months. His lower limbs weakness and spasticity were 
initially episodic with full recovery without treatment. Later 
it became more frequent and affected his daily activity. He 
also complained of urinary hesitancy and recurrent multiple 
painful genitalia and oral ulcers. He was treated with oral 
carbamazepine 200 mg daily for lower limbs spasticity. 
Subsequently, he developed cerebellar signs, dysarthria, 
nystagmus, and intentional tremor. MRI of brain and spine 
was performed to rule out compressive myelopathy and the 
result was normal. Blood investigations for sexual commu-
nicable diseases and autoimmune diseases were negative. 
Based on clinical finding and inconclusive investigations, 
he was diagnosed as primary spinocerebellar degeneration 
with a differential diagnosis of vasculitic Behçet’s. Despite 
Figure 1 Oral ulcer at the posterior aspect of the tongue (red arrow).
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Table 1 Summary of clinical presentation and treatment for both cases
Cases Clinical presentation Treatment
Case 1 47-year-old man
2001 Behçet’s disease with bilateral panuveitis Oral prednisolone 80 mg daily (1.5 mg/kg/day) with tapering dose 5 mg/week
Topical prednisolone acetate 1% 4-hourly for both eyes
2002–2012 Defaulted follow-up No treatment
2013 Upper limb weakness Analgesic
Physiotherapy
2014 Defaulted follow-up No treatment
2015–2016 Neuro-Behçet’s with bilateral optic atrophy Intravenous methylprednisolone 1 g/day for 5 days followed by oral 
prednisolone 40 mg daily for 3 months
Then oral prednisolone was tapered down slowly to a maintenance dose of 
20 mg daily
Oral azathioprine 25 mg daily started during tapering dose of oral prednisolone
Case 2 25-year-old man
2014 Primary spinocerebellar degeneration Oral carbamazepine 200 mg daily for lower limbs spasticity
2015–2016 Neuro-Behçet’s with bilateral panuveitis complicated 
with neovascular glaucoma in the right eye
Intravenous methylprednisolone 1 g/day for 5 days followed by oral 
prednisolone 50 mg daily
Then oral prednisolone was tapered down slowly
Topical antiglaucoma for high intraocular pressure
Blebitis post-trabeculectomy and subsequently 
developed endophthalmitis of the right eye
Intravenous, intravitreal, and topical antibiotic
Recurrent attacks of posterior uveitis of the left eye Higher dose of oral prednisolone and addition of oral cyclosporine
A B C
Figure 2 Magnetic resonance imaging of the brain showed small round multiple hyperintense lesions at bifrontal lobes on T2-weighted (A) and fluid-attenuated inversion 
recovery images (B) (red arrows). The lesions were not seen on T1-weighted image (C)
A B
Figure 3 Right eye showed rubeosis iridis with ectropion uvea and hypopyon (blue 
arrow) (A) and mild anterior segment inflammation in the left eye (B).
being on treatment, his limb weakness progressed. He was 
paraplegic and wheel chair dependent.
One year after his initial presentation, he developed pain-
ful right eye with reduction of vision for 3 weeks. He was 
then referred to ophthalmology team for further eye assess-
ment. Retrospectively, he had history of right eye painless 
progressive blurring of vision for the past 1 year. His vision 
was perception to light on the right eye while left eye vision 
was 6/12. Ocular examination showed the presence of bilat-
eral uveitis. Anterior segment of the right eye revealed severe 
anterior chamber inflammation with the presence of hypo-
pyon, 360 degree rubeosis iridis with ectropion uvea (Figure 
3A), and dense diffuse vitritis that impaired the visualization 
of the fundus. There was mild anterior segment inflammation 
in the left eye (Figure 3B) with the presence of mild vitritis 
and vitreous opacities. There was no vasculitis, retinitis, or 
retinal hemorrhage and exudate seen in the left eye. Right 
eye was complicated with neovascular glaucoma with IOP 
of 44 mmHg. IOP of left eye was 14 mmHg.
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Further assessment was performed to support the diag-
nosis of BD; pathergy test positive (Figure 4). Screening 
for infective and connective tissue diseases was negative. 
Another MRI of the brain revealed atrophy of the cerebellar 
and frontal lobe (Figure 5). He refused lumbar puncture. 
He was diagnosed as neuro-Behçet’s based on progressive 
neurological deficits of the lower limbs, recurrent mul-
tiple painful genitalia and oral ulcers, bilateral uveitis, and 
positive pathergy test. He was then treated with intravenous 
methylprednisolone 1 g daily for 5 days followed by oral 
prednisolone 50 mg daily. His IOP was not controlled with 
antiglaucoma drugs, and right eye augmented trabeculectomy 
was performed (Figure 6A and B). However, the bleb site was 
complicated with suture abscess (Figure 6C) and followed 
with blebitis (Figure 6D), then subsequently developed endo-
phthalmitis. In view of that, the oral prednisolone was tapered 
down slowly. Despite being on intravenous, intravitreal, 
and topical antibiotic, the right eye progressed to painless 
blind eye. There was no progression of neurological deficit 
throughout follow-up. However, he continued to develop 
recurrent attacks of posterior uveitis of the left eye. Ocular 
inflammation was well controlled with higher doses of oral 
prednisolone and addition of oral cyclosporine. The summary 
of clinical presentation and treatment is shown in Table 1.
Discussion
Neuro-Behçet’s is rare, yet the most debilitating complica-
tion of BD. The incidence was reported as 4%–59% among 
BD.14–18 Unlike BD, neuro-Behçet’s is more common in men 
than in women with a male-to-female ratio of 3.4:1 to 4:1.8,17 
Our reported case series involved young to middle-aged Asian 
men. Commonly neurological manifestations develop after 
several years of development of BD, ranging from 3 to 6 
years.5,8,9 The onset of neuro-Behçet’s was rather delayed in 
case 1, 12 years after the presentation of recurrent uveitis and 
ulcers. Joseph and Scolding reported a mean duration of 12 
years from the onset of BD in 22 cases of neuro-Behçet’s.19 
There were differences in the clinical presentation of both 
cases, but both fulfilled the criteria of neuro-Behçet’s based 
on International Consensus Recommendation (ICR) criteria 
for neuro-Behçet’s diagnosis.20
However, in 6% of cases of neuro-Behçet’s, neurological 
manifestation precedes the systemic symptoms of BD.8 This 
Figure 4 Positive pathergy test showed pustular lesion following 24–48 hours of 
23-gauge sterile needle injected subcutaneously.
Figure 5 Magnetic resonance imaging of the brain showed atrophy of the brainstem 
(red arrow).
A B
C D
Figure 6 Right eye post-trabeculectomy (A) with close-up view (B), complicated 
with suture abscess (blue arrow) (C) and followed with blebitis (D).
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may perhaps lead to difficulty in diagnosis, as illustrated in 
case 2. The presence of urinary hesitancy and genital ulcers 
may lead to other possible diagnoses, especially in a young 
healthy man. Spinal and cerebellar sign and symptoms 
may easily mimic spinocerebellar degeneration or multiple 
system atrophy.21 Diagnosis of neuro-Behçet’s is difficult in 
nonestablished BD.
BD is rare in Malaysia, and no case of neuro-Behçet’s 
has ever been reported in Malaysia. We reported two cases 
of neuro-Behçet’s who presented with ocular involvement at 
different courses of the disease. Based on ICR criteria, case 
1 is a case of definite neuro-Behçet’s and case 2 is probable 
neuro-Behçet’s at the beginning of the course of the disease. 
Ocular involvement was at the initial course of the disease 
in case 1, while in case 2, it was at the later stage of the dis-
ease. However, complications of severe ocular inflammation 
resulted in visual impairment and blindness in both cases. 
The most common ocular manifestation in BD is retinal 
vessel inflammatory changes, periphlebitis and periarteritis, 
serofibrinous anterior uveitis, and panuveitis.22–27
In both cases, although both eyes were affected, ocular 
manifestations were more severe in one eye. Nongranu-
lomatous panuveitis was seen in both cases, with retinal 
inflammation. Case 2 presented with complications of severe 
uveitis, neovascular glaucoma, and cataract during the initial 
presentation. The Systemic Immunosuppressive Therapy for 
Eye Disease Cohort study reported that 10% of BD with 
posterior ocular involvement developed cataract compared 
with 6% of the cases with anterior uveitis, while secondary 
glaucoma is observed in 19% of BD with anterior uveitis, 
and only 13% of BD with posterior or panuveitis.24 Elgin et 
al reported that ~11% of BD patients developed secondary 
glaucoma. Half of the secondary glaucoma cases were ste-
roid- or inflammation-induced open-angle glaucoma, while 
only 10% developed neovascular glaucoma.28
Addressing elevation of IOP in cases of BD with neo-
vascular glaucoma is always frustrating. Neovascular glau-
coma is a refractory glaucoma that usually requires surgical 
intervention, glaucoma drainage device implantation, or 
augmented trabeculectomy. On the other hand, the inflam-
mation in BD requires treatment with high dose of systemic 
steroids or other immunosuppressive treatment.27,29,30 Immu-
nosuppressive treatment increases the risk of infection. In 
case 2, patient developed endophthalmitis after augmented 
trabeculectomy and lost his vision.
To date, there is no reported study on the relationship of 
severe ocular inflammation and neuro-Behçet’s. In addition, 
there was no single report on the specific test able to predict 
the manifestation of neuro-Behçet’s in BD patients. Based 
on their clinical presentation, both cases presented with 
parenchymal neuro-Behçet’s. Parenchymal neuro-Behçet’s 
is characterized by focal or multifocal involvement of brain 
parenchyma, leading to hemiparesis, corticospinal tract or 
pyramidal signs, brainstem, and cerebellar signs.8,9,20,31–33
MRI findings in neuro-Behçet’s include small focal or 
multifocal lesions of high signal intensity on T2-weighted 
images (Figure 2) and iso- or hypointense lesions on 
T1-weighted images.2,20 The lesion occurs most frequently 
within the brainstem, followed by thalamus and basal gan-
glia.2 The presence of brainstem–thalamic–basal ganglia 
lesions can strongly support the diagnosis of acute/subacute 
parenchymal neuro-Behçet’s and raise the possibility of BD 
when the systemic features are scarce.34 This lesion represents 
inflammatory cellular infiltration, demyelination, and edema, 
which may diminish post-treatment with corticosteroid and/
or immunosuppressive agents.2 In chronic disease as in case 
2, atrophic lesions can be found in brainstem (Figure 4).
Pathergy test may perhaps assist in making the definitive 
diagnosis. Although positive pathergy test is one of the criteria 
for diagnosis of BD, it is not pathognomonic of BD.20 Pathergy 
test was negative in case 1 but positive in case 2. Other test 
includes CSF examination and major histocompatibility com-
plex human leukocyte antigen (HLA) B-5 allele and HLA B-51.
Till date no controlled or comparative trials have 
evaluated treatment of neuro-Behçet’s. Both of our patients 
received intravenous methylprednisolone 1 g/day for 5 days 
followed by maintenance oral corticosteroids. ICR recom-
mended early consideration of a disease-modifying therapy 
such as AZT when one or more poor prognostic features 
are encountered. Poor prognostic factors include brainstem 
or spinal cord presentation, frequent relapses, early disease 
progression, and high CSF pleocytosis.8,17,31 AZT was added 
to systemic steroids because of frequent relapses in case 
1. Both cases resulted in visual impairment and blindness 
with neurological deficit. BD and neuro-Behçet’s patients 
should understand their course of the disease, especially the 
symptoms of ocular and systemic relapse, to avoid delay in 
seeking medical attention.
Conclusion
It is important to consider neuro-Behçet’s in neurological 
patients with unexplained findings. Detection and thorough 
investigation for any nongranulomatous uveitis may help in 
early diagnosis of BD and neuro-Behçet’s. Creating aware-
ness and better understanding of BD and neuro-Behçet’s may 
prevent ocular and systemic complications.
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